Showing 15 posts of 219 posts found.


AbbVie’s Aquipta receives MHRA marketing authorisation

September 5, 2023
Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …


AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

July 25, 2023
Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …

Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership

June 20, 2023
Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership

Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

May 11, 2021
Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …


AbbVie funds Mitokinin’s Parkinson’s research with option to buy

March 3, 2021
Research and Development AbbVie, Mitokinin, Parkinson's

AbbVie has landed an option to buy neurodegenerative disease-focused biotech Mitokinin following completion of investigational new drug (IND)-enabling studies on …


AbbVie’s rheumatoid arthritis drug Rinvoq approved for NHS Scotland

February 9, 2021
Manufacturing and Production AbbVie, rheumatoid arthritis

The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for use on the NHS in …


AbbVie’s psoriatic arthritis and ankylosing spondylitis drug gets EU approval

January 26, 2021
Manufacturing and Production AbbVie

The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for …


AbbVie buys COVID-19 antibody licence from Harbour BioMed

December 16, 2020
Research and Development AbbVie, COVID-19, Harbour BioMed, antibody

Harbour BioMed (HBM) and Utrecht University (UU) have announced that their fully human, SARS-CoV-2 neutralising antibody 47D11 and programme, has …


AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis

December 10, 2020
Research and Development AbbVie, upadacitinib

AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …


NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020
Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …


AbbVie’s Rinvoq smashes Phase 3 efficacy targets in atopic dermatits

July 22, 2020
Research and Development AbbVie, atopic dermatits, pharma, upadacitinib

AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy …


FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

June 29, 2020
Sales and Marketing AbbVie, Allergan, FDA, pharma

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for …


AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

June 15, 2020
Sales and Marketing AbbVie, leukaemia

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …


AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn

June 11, 2020
Research and Development AbbVie, Genmab, partnership, pharma

AbbVie has joined forces with Genmab to develop and commercialise three of the latter’s early-stage Genmab drug products – epcoritamab …

Latest content